{
  "main_header": {
    "sid": 1142904,
    "name": "Egetis Therapeutics AB",
    "stock_name": "Egetis Therapeutics AB",
    "full_name": "Egetis Therapeutics AB",
    "name_url": "stocks-analysis/egetis-therapeutics-ab",
    "exchange": 1025,
    "exchangecode": "OME",
    "country_id": 29,
    "currency": "SEK",
    "cmp": "4.76",
    "chg": -0.21,
    "chgp": "-4.23%",
    "dir": -1,
    "prev_price": "4.97",
    "mcapval": "2,588.31",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "OMX Stockholm 30",
    "isin": "SE0003815604",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.33 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/egetis-therapeutics-ab-1142904-1025&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Egetis Therapeutics AB Reports Negative Financial Performance Amidst Strong Cash Position",
        "link": "https://www.marketsmojo.com/news/mojo-premium/egetis-therapeutics-ab-enters-hidden-turnarounds-strategy-due-to-financial-resilience-3526191",
        "imagepath": "",
        "date": "2025-09-17 17:15:16",
        "description": "<p><strong>Egetis Therapeutics AB</strong>, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending March 2025. The report indicates a challenging period for the company, with a net profit recorded at SEK -176 MM, reflecting negative financial performance.</p>\n\n<p>Despite the downturn in profitability, <strong>Egetis Therapeutics AB</strong> has managed to maintain a robust cash position, with cash and equivalents reaching SEK 623.8 MM. This substantial liquidity may provide the company with the necessary resources to navigate its current challenges and invest in future growth opportunities.</p>\n\n<p>Another noteworthy aspect of the financial report is the company's debt-equity ratio, which stands at -38.38%. This indicates that <strong>Egetis Therapeutics AB</strong> is debt-free, a factor that could enhance its financial stability..."
      }
    ],
    "total": 1,
    "sid": "1142904",
    "stock_news_url": "https://www.marketsmojo.com/news/egetis-therapeutics-ab-1142904"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Egetis Therapeutics AB Reports Negative Financial Performance Amidst Strong Cash Position

2025-09-17 17:15:16

Egetis Therapeutics AB, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending March 2025. The report indicates a challenging period for the company, with a net profit recorded at SEK -176 MM, reflecting negative financial performance.

Despite the downturn in profitability, Egetis Therapeutics AB has managed to maintain a robust cash position, with cash and equivalents reaching SEK 623.8 MM. This substantial liquidity may provide the company with the necessary resources to navigate its current challenges and invest in future growth opportunities.

Another noteworthy aspect of the financial report is the company's debt-equity ratio, which stands at -38.38%. This indicates that Egetis Therapeutics AB is debt-free, a factor that could enhance its financial stability...

Read More

View All News